TY - JOUR
T1 - BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer
AU - Le Pottier, Laëtitia
AU - Bendaoud, Boutahar
AU - Dueymes, Maryvonne
AU - Daridon, Capucine
AU - Youinou, Pierre
AU - Shoenfeld, Yehuda
AU - Pers, Jacques Olivier
PY - 2007/5
Y1 - 2007/5
N2 - Intravenous immunoglobulin (IVIg) has been used to treat autoimmune diseases and lymphoid malignancies with some therapeutic effect. In both these pathological conditions, there is an overproduction of BAFF (for "B-cell-activating factor of the TNF family"), and APRIL (for "a proliferation-inducing ligand"). The presence of antibodies (Abs) with BAFF and APRIL specificities in IVIg preparations was investigated by enzyme-linked immunosorbent assay, and Western Blot analysis. Apoptosis was measured by the annexin-V binding method, and confirmed using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling technique. Nonglycosylated recombinant BAFF, glycosylated affinity-purified BAFF, and recombinant APRIL (but not TNFα), were recognized by certain IgG in IVIg, and their F(ab′)2 fragments. Steric hindrance prevented the antiapoptotic effects of BAFF on B-lymphocytes. This work documents the presence of anti-BAFF and anti-APRIL Abs in IVIg. These can functionally neutralize the role of BAFF in B-cell survival. These anti-BAFF IgG might amend deleterious effects of BAFF in B-cell-mediated autoimmune diseases.
AB - Intravenous immunoglobulin (IVIg) has been used to treat autoimmune diseases and lymphoid malignancies with some therapeutic effect. In both these pathological conditions, there is an overproduction of BAFF (for "B-cell-activating factor of the TNF family"), and APRIL (for "a proliferation-inducing ligand"). The presence of antibodies (Abs) with BAFF and APRIL specificities in IVIg preparations was investigated by enzyme-linked immunosorbent assay, and Western Blot analysis. Apoptosis was measured by the annexin-V binding method, and confirmed using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling technique. Nonglycosylated recombinant BAFF, glycosylated affinity-purified BAFF, and recombinant APRIL (but not TNFα), were recognized by certain IgG in IVIg, and their F(ab′)2 fragments. Steric hindrance prevented the antiapoptotic effects of BAFF on B-lymphocytes. This work documents the presence of anti-BAFF and anti-APRIL Abs in IVIg. These can functionally neutralize the role of BAFF in B-cell survival. These anti-BAFF IgG might amend deleterious effects of BAFF in B-cell-mediated autoimmune diseases.
KW - Apoptosis
KW - Autoimmune disease
KW - B lymphocyte-stimulator (BLyS)
KW - B-cell activating factor of the TNF family (BAFF)
KW - Cancer
KW - Intravenous immunoglobulin
UR - http://www.scopus.com/inward/record.url?scp=34249095844&partnerID=8YFLogxK
U2 - 10.1007/s10875-007-9082-2
DO - 10.1007/s10875-007-9082-2
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:34249095844
SN - 0271-9142
VL - 27
SP - 257
EP - 265
JO - Journal of Clinical Immunology
JF - Journal of Clinical Immunology
IS - 3
ER -
